Compare Invesco DB Oil Fund (DBO) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco DB Oil Fund vs Revvity Inc — how do they compare? Invesco DB Oil Fund trades at $24.13 (market cap $255.13M), while Revvity Inc trades at $154.18 (market cap $16.98B). The key difference: Revvity Inc is far larger — about 66.6× Invesco DB Oil Fund's market cap, and Revvity Inc pays a 0.18% dividend while Invesco DB Oil Fund pays none. Which is the better fit depends on your goals — on Pluang, investors hold Invesco DB Oil Fund for 31 Days and Revvity Inc for 12 Days on average.
| DBO | RVTY | |
|---|---|---|
Market Cap | $255.13M | $16.98B |
Volume | 562,167 | 1,456,900 |
Sector | Commodities - Energy | Health |
52-Week High | $26.35 | $157.36 |
52-Week Low | $11.98 | $82.26 |
Typical Hold Time | 31 Days | 12 Days |
Enterprise Value | — | $19.30B |
Dividend Yield | — | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DBO trades at $24.13, up 2.51% today amid mixed oil market signals. Technical indicators show a neutral overall signal with bearish moving averages, while oscillators remain neutral. Recent news highlights Middle East supply disruptions and OPEC+ production decisions creating volatility in energy markets. The stock faces resistance at $24 and support at $23 levels.
The outlook remains uncertain with geopolitical tensions supporting oil prices but strategic reserve releases creating downward pressure. Key risks include supply chain disruptions and regulatory challenges, while institutional sentiment appears cautious given the mixed technical signals and market volatility.
Revvity (RVTY) trades at $154.18, up 0.38% today and near its 52-week high of $158.28. The stock shows a bullish technical trend with strong moving averages and has beaten earnings estimates for the last three quarters. Recent developments include the launch of a new diabetes screening kit in Europe and the acquisition of Human Cell Design to expand its metabolic disease research tools. Revenue remains stable around $2.9 billion, though net income margin is modest at 8.16%.
The outlook is positive with analyst consensus leaning buy (51.72%) and a price target of $132.13, though the current price exceeds it. Key opportunities include diagnostic growth and AI-driven demand, while risks involve premium valuation (P/E 73.15), margin pressures, and exposure to China market volatility. Earnings on November 3, 2026, will be critical for near-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Invesco DB Oil Fund
DBO provides exposure to WTI crude oil prices through futures contracts. It is designed for investors seeking a way to invest in the performance of the fossil fuel market without purchasing physical oil barrels.
Read more on DBO →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
